Core Insights - Breast cancer is the most common malignant tumor threatening women's health in China, with HR+/HER2- subtype accounting for approximately 70% of diagnosed cases [1][2] - Early diagnosis and treatment significantly improve prognosis for HR+/HER2- breast cancer patients, but 20%-30% of patients face recurrence risks due to late-stage diagnosis [2] - The introduction of CDK4/6 inhibitors has improved the five-year survival rate, yet some advanced breast cancer patients develop resistance to these treatments [2] - PAM pathway gene testing is crucial for patients who develop endocrine therapy resistance, as over 60% of these patients may have PAM pathway mutations [2] - Precision treatment strategies targeting PAM pathway mutations have become mainstream in late-stage breast cancer management, enhancing patient outcomes [2] Industry Developments - There is an increasing number of innovative breast cancer drugs in research and clinical application, providing more treatment options for patients [3] - Cost remains a significant factor in treatment decisions, and there is a strong expectation for new drugs to be included in health insurance coverage to improve patient access [3]